Read time: 2 minutes
By: McKesson Health Systems Editorial Team
Specialty pharmacies foresee a growing pipeline of specialty drugs, ultimately allowing for more outpatient treatment options for patients. Anticipated government intervention on cost control for drugs, 340B reforms, and PBM restrictions are believed to be on the horizon.
Access our comprehensive and exclusive 2024 Health Systems Specialty Pharmacy Research Report below to learn more.
Share
Post
Post
Email